You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Respiratory
Novartis to build new radioligand therapy site in Texas
Login
Username:

Password:


Related Headlines

GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers

FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer

GSK secures China approval for Exdensur to treat nasal polyp condition

Dexcel Pharma's Nintedanib Capsules approved for US launch

Gilead to acquire Tubulis to expand ADC oncology capabilities

Sanofi reports positive phase 2 results for lunsekimig in asthma and CRSwNP

Akeso reports updated data on cadonilimab combination therapy in PD-(L)1 inhibitor-resistant advanced NSCLC data

Parnell launches first FDA-approved generic florfenicol and flunixin combination for bovine respiratory disease

Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal

ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children

4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion

Almirall reports lebrikizumab demonstrated sustained long-term control in atopic dermatitis through four years

AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials

Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator

Akeso's Phase II trials of AK146D1 and AK138D1 approved in China

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026